Norman, Maia http://orcid.org/0000-0002-9654-4904
Ter-Ovanesyan, Dmitry
Trieu, Wendy
Lazarovits, Roey
Kowal, Emma J. K.
Lee, Ju Hyun
Chen-Plotkin, Alice S.
Regev, Aviv
Church, George M.
Walt, David R. http://orcid.org/0000-0002-5524-7348
Funding for this research was provided by:
Chan Zuckerberg Initiative (CZI) Neurodegeneration Challenge Network, Good Ventures
Article History
Received: 29 October 2020
Accepted: 5 May 2021
First Online: 3 June 2021
Competing interests
: D.R.W. is a founder and equity holder of Quanterix. A.R. is an SAB member of Thermo Fisher Scientific, Neogene Therapeutics, Asimov and Syros Pharmaceuticals. A.R. is a cofounder of and equity holder in Celsius Therapeutics and an equity holder in Immunitas. From 1 August 2020, A.R. is an employee of Genentech. G.M.C. is a founder, consultant or advisory board member to companies listed here: ExternalRef removed. These companies had no influence over any aspect of this research. We have filed intellectual property on methods for EV analysis and isolation. M.N., D.T.-O. and D.R.W. filed a provisional patent for the measurement of EVs using single-molecule arrays as described in this study. Additionally, D.T.-O., E.J.K.K., A.R. and G.M.C. filed intellectual property relating to the identification and use of new candidate markers for NDEV isolation.